Key result
Combined treatment with cromakalim and tedisamil abolished sustained ventricular fibrillation (0% vs 64% in control, p<0.05) and increased coronary flow independently in isolated rat hearts.
Population
Isolated rat hearts subjected to 30-min regional ischaemia
Comparison
Combined administration of cromakalim and… vs Control, cromakalim alone, and tedisamil alone
Design
Preclinical
Follow-up
30 minutes
Authors
Loading...
Does not alter clinical practice; leaves open translation of combined K+ channel effects to in vivo or human ischemia models.
Absolute Event Rate: 0% vs 64%
p-value: p=< 0.05
The combination of tedisamil and cromakalim in isolated rat hearts provides independent beneficial effects on ischemia-induced sustained ventricular fibrillation and coronary flow.
Rees et al. (1993) studied Ischaemia-induced ventricular fibrillation (n=115). Combined administration of cromakalim and tedisamil vs. Control, tedisamil alone, cromakalim alone was evaluated on Incidence of sustained ventricular fibrillation (SVF) (p=< 0.05). Combined treatment with cromakalim and tedisamil abolished sustained ventricular fibrillation (0% vs 64% in control, p<0.05) and increased coronary flow independently in isolated rat hearts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: